EPAS1 and renal cell adenocarcinoma: The treatment of RCC cells with hypoxia-induced factor 2α (HIF2α) and vascular endothelial growth factor (VEGF) inhibitors, showed that RCC progression could be suppressed, suggesting an important key role of HIF2α/VEGF signaling in RCC progression.